2023
Zielinski M, Peralta Reyes FS, Gremer L, Schemmert S, Frieg B, Schäfer LU, Willuweit A, Donner L, Elvers M, Nilsson LNG, Syvänen S, Sehlin D, Ingelsson M, Willbold D, Schröder GF. Cryo-EM of Aβ fibrils from mouse models find tg-APPArcSwe fibrils resemble those found in patients with sporadic Alzheimer's disease. Nat Neurosci. 2023 Dec;26(12):2073-2080. doi: 10.1038/s41593-023-01484-4. Epub 2023 Nov 16. PMID: 37973869
Kutzsche J, Schemmert S*, Bujnicki T, Zafiu C, Halbgebauer S, Kraemer-Schulien V, Pils M, Blömeke L, Post J, Kulawik A, Jürgens D, Rossberg W. M, Hümpel M, Bannach O, Otto M, Araujo J.A, Willuweit A, Willbold D. Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs – A model of sporadic Alzheimer’s disease. Heliyon, 2023, e18443, doi: 10.1016/j.heliyon.2023.e18443.
Altendorf T, Gering I, Santiago-Schübel B, Aghabashlou Saisan S, Tamgüney G, Tusche M, Honold D, Schemmert S, Hoyer W, Mohrlüder J, Willbold D. Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer's Disease and Other Tauopathies. Int J Mol Sci. 2023 Jan 21;24(3):2161. doi: 10.3390/ijms24032161.
2022
Kass B, Schemmert S, Zafiu C, Pils M, Bannach O, Kutzsche J, Bujnicki T, Willbold D. Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo. Cell Rep Med. 2022 May 17;3(5):100630. doi: 10.1016/j.xcrm.2022.100630.
Törner R, Kupreichyk T, Gremer L, Debled EC, Fenel D, Schemmert S, Gans P, Willbold D, Schoehn G, Hoyer W, Boisbouvier J. Structural basis for the inhibition of IAPP fibril formation by the co-chaperonin prefoldin. Nat Commun. 2022 May 2;13(1):2363. doi: 10.1038/s41467-022-30042-y.
2021
Willuweit A, Schöneck M, Schemmert S, Lohmann P, Bremen S, Honold D, Burda N, Jiang N, Beer S, Ermert J, Willbold D, Shah NJ, Langen KJ. Comparison of the Amyloid Load in the Brains of Two Transgenic Alzheimer's Disease Mouse Models Quantified by Florbetaben Positron Emission Tomography. Front Neurosci. 2021 Oct 4;15:699926. doi: 10.3389/fnins.2021.699926. eCollection 2021.
Camargo LC, Honold D, Bauer R, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Willuweit A, Schemmert S. Sex-Related Motor Deficits in the Tau-P301L Mouse Model. Biomedicines. 2021 Sep 4;9(9):1160. doi: 10.3390/biomedicines9091160.
Camargo LC, Schöneck M, Sangarapillai N, Honold D, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Schemmert S, Willuweit A. PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease. Int J Mol Sci. 2021 Jun 30;22(13):7062. doi: 10.3390/ijms22137062.
Schemmert S, Camargo LC, Honold D, Gering I, Kutzsche J, Willuweit A, Willbold D. In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer's Disease. Int J Mol Sci. 2021 Jun 18;22(12):6553. doi: 10.3390/ijms22126553.
Elfgen A, Santiago-Schübel B, Hupert M, Schemmert S, Schartmann E, Tusche M, Gering I, Zafiu C, Kutzsche J. Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid. Eur J Pharm Sci. 2021 Jan 1;156:105581. doi: 10.1016/j.ejps.2020.105581. Epub 2020 Oct 6. PMID: 33035662
2019
Schemmert S, Schartmann E, Honold D, Zafiu C, Ziehm T, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D. Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2. Neurobiol Dis. 2019 Apr;124:36-45. doi: 10.1016/j.nbd.2018.10.021. Epub 2018 Nov 2.
Schemmert S, Schartmann E, Zafiu C, Kass B, Hartwig S, Lehr S, Bannach O, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D. Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology. Mol Neurobiol. 2019 Mar;56(3):2211-2223. doi: 10.1007/s12035-018-1209-3. Epub 2018 Jul 12.
2018
Dunkelmann T.*, Schemmert S.*, Honold D., Teichmann K., Butzküven E., Demuth H-U., Shah N. J., Langen K-J., Kutzsche J., Willbold D., Willuweit A. (2018) Comprehensive characterization of the pyroglutamate Aβ induced motor neurodegenerative phenotype of TBA2.1 mice. J Alzheimers Dis. 2018;63 (1):115-130. *author contribute equally
Schartmann E., Schemmert S., Niemietz N., Honold D., Ziehm T., Tusche M., Elfgen A., Gering I., Brener O., Shah N.J., Langen K-J., Kutzsche J., Willbold D., Willuweit A. (2018) In vitro potency and preclinical pharmacokinetic comparison of all-D-enantiomeric peptides developed for the treatment of Alzheimer’s disease. J Alzheimers Dis. 2018;64(3):859-873. doi: 10.3233/JAD-180165.
2017
Dunkelmann T., Teichmann K., Ziehm T., Schemmert S., Frenzel D., Tusche M. Dammers C., Jürgens D., Demuth H-U., Langen K-J., Kutzsche J., Willuweit A., Willbold D. (2018) Aβ oligomer eliminating compounds interfere successfully with pEAβ(3–42) induced motor neurodegenerative phenotype in transgenic mice. Neuropeptides. 2018 Feb;67:27-35. doi: 10.1016/j.npep.2017.11.011. Epub 2017 Nov 27.
Hupert M, Elfgen A., Schartmann E., Schemmert S., Buscher B., Kutzsche J., Willbold D., Santiago-Schubel B. (2017) Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-beta oligomer eliminating all-D-enantiomeric peptide RD2 in mouse plasma. Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 15;1073:123-129. doi: 10.1016/j.jchromb.2017.12.009. Epub 2017 Dec 8.
Kutzsche J.*, Schemmert S.*, Tusche M., Neddens J., Rabl R., Jürgens D., Brener O., Willuweit A., Hutter-Paier B., Willbold D. (2017) Large-Scale Oral Treatment Study with the Four Most Promising D3 Derivatives for the Treatment of Alzheimer’s Disease. Molecules. 2017 Oct 10;22(10):1693. doi: 10.3390/molecules22101693. PMID: 28994710.
van Groen T., Schemmert S., Brener O., Gremer L., Ziehm T., Tusche M., Nagel-Steger L., Kadish I., Schartmann E., Elfgen A., Jurgens D., Willuweit A., Kutzsche J., Willbold D. (2017) The Aβ oligomer eliminating d-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Sci Rep. 2017 Nov 24;7(1):16275. doi: 10.1038/s41598-017-16565-1.
Schartmann E, Schemmert S, Ziehm T, Leithold LHE, Jiang N, Tusche M, Joni Shah N, Langen KJ, Kutzsche J, Willbold D, Willuweit A. Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease.
Eur J Pharm Sci. 2018 Mar 1;114:93-102. doi: 10.1016/j.ejps.2017.12.005. Epub 2017 Dec 7.
